AllianceBernstein’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-808,046
| Closed | -$31M | – | 3225 |
|
|
2023
Q2 | $31M | Buy |
808,046
+755,526
| +1,439% | +$19.4M | 0.01% | 725 |
|
|
2023
Q1 | $1.22M | Hold |
52,520
| – | – | ﹤0.01% | 2127 |
|
|
2022
Q4 | $1.38M | Buy |
52,520
+17,400
| +50% | +$385K | ﹤0.01% | 2120 |
|
|
2022
Q3 | $690K | Hold |
35,120
| – | – | ﹤0.01% | 2490 |
|
|
2022
Q2 | $614K | Buy |
35,120
+1,300
| +4% | +$20.4K | ﹤0.01% | 2592 |
|
|
2022
Q1 | $553K | Buy |
33,820
+100
| +0.3% | +$1.36K | ﹤0.01% | 2631 |
|
|
2021
Q4 | $550K | Buy |
33,720
+2,100
| +7% | +$29.9K | ﹤0.01% | 2696 |
|
|
2021
Q3 | $403K | Hold |
31,620
| – | – | ﹤0.01% | 2843 |
|
|
2021
Q2 | $446K | Buy |
31,620
+7,400
| +31% | +$118K | ﹤0.01% | 2862 |
|
|
2021
Q1 | $376K | Hold |
24,220
| – | – | ﹤0.01% | 2809 |
|
|
2020
Q4 | $384K | Sell |
24,220
-2,600
| -10% | -$39.2K | ﹤0.01% | 2723 |
|
|
2020
Q3 | $326K | Hold |
26,820
| – | – | ﹤0.01% | 2771 |
|
|
2020
Q2 | $310K | Buy |
26,820
+3,120
| +13% | +$43K | ﹤0.01% | 2860 |
|
|
2020
Q1 | $325K | Buy |
23,700
+3,440
| +17% | +$40.7K | ﹤0.01% | 2585 |
|
|
2019
Q4 | $120K | Sell |
20,260
-200
| -1% | -$1.09K | ﹤0.01% | 3011 |
|
|
2019
Q3 | $108K | Sell |
20,460
-680
| -3% | -$4.51K | ﹤0.01% | 3069 |
|
|
2019
Q2 | $163K | Buy |
21,140
+180
| +0.9% | +$2.74K | ﹤0.01% | 3010 |
|
|
2019
Q1 | $417K | Buy |
20,960
+6,660
| +47% | +$116K | ﹤0.01% | 2604 |
|
|
2018
Q4 | $189K | Buy |
14,300
+1,060
| +8% | +$21.2K | ﹤0.01% | 2901 |
|
|
2018
Q3 | $487K | Buy |
13,240
+800
| +6% | +$25.7K | ﹤0.01% | 2632 |
|
|
2018
Q2 | $435K | Sell |
12,440
-4,000
| -24% | -$153K | ﹤0.01% | 2668 |
|
|
2018
Q1 | $764K | Sell |
16,440
-5,820
| -26% | -$213K | ﹤0.01% | 2372 |
|
|
2017
Q4 | $835K | Buy |
22,260
+13,000
| +140% | +$568K | ﹤0.01% | 2370 |
|
|
2017
Q3 | $493K | Hold |
9,260
| – | – | ﹤0.01% | 2577 |
|
|
2017
Q2 | $528K | Buy |
9,260
+1,040
| +13% | +$52.2K | ﹤0.01% | 2592 |
|
|
2017
Q1 | $442K | Sell |
8,220
-660
| -7% | -$37.3K | ﹤0.01% | 2579 |
|
|
2016
Q4 | $506K | Hold |
8,880
| – | – | ﹤0.01% | 2559 |
|
|
2016
Q3 | $552K | Sell |
8,880
-1,180
| -12% | -$83.4K | ﹤0.01% | 2497 |
|
|
2016
Q2 | $569K | Buy |
10,060
+5,300
| +111% | +$322K | ﹤0.01% | 2473 |
|
|
2016
Q1 | $305K | Buy |
4,760
+1,680
| +55% | +$136K | ﹤0.01% | 2583 |
|
|
2015
Q4 | $433K | Buy |
3,080
+580
| +23% | +$78.8K | ﹤0.01% | 2502 |
|
|
2015
Q3 | $242K | Sell |
2,500
-200
| -7% | -$23.8K | ﹤0.01% | 2723 |
|
|
2015
Q2 | $409K | Buy |
+2,700
| New | +$446K | ﹤0.01% | 2658 |
|
AllianceBernstein's KDNY Position: Q3 2023 in Review
AllianceBernstein sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 808,046 shares — an estimated $31M sold.
AllianceBernstein first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $31M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- AllianceBernstein reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- AllianceBernstein sold 808,046 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $31M.
- AllianceBernstein first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- AllianceBernstein's Chinook Therapeutics, Inc. Common Stock position peaked at $31M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on AllianceBernstein's 13F filing for Q3 2023, filed 14 Nov 2023.